市場調査レポート
商品コード
1410835
KRAS検査の世界市場 - 市場規模(セグメント別)、シェア、規制、償還、処置、予測(~2033年)KRAS Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
KRAS検査の世界市場 - 市場規模(セグメント別)、シェア、規制、償還、処置、予測(~2033年) |
出版日: 2023年12月08日
発行: GlobalData
ページ情報: 英文
納期: 即納可能
|
当レポートでは、世界のKRAS検査市場について調査分析し、各セグメントの市場規模、市場動向、競合情勢、COVID-19の影響などの情報を提供しています。
市場モデルの主な内容は以下の通りです。
上市済みのKRAS検査と進化する競合情勢
世界、地域、国レベルの市場固有の考察
医療制度の概要を含む真の全体像を把握することで、市場の理解を促進します。また、市場参入セグメントでは、償還政策や規制情勢についての情報を提供し、市場力学をより深く掘り下げることができます。
対象企業
Not Applicable
Not Applicable
KRAS Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.
The model discusses in detail the impact of COVID-19 on KRAS Tests market for the year 2020 and beyond. Colorectal cancer (CRC) is the third most common cancer in men and the second most common cancer in women. Approximately 1.8 million new CRC incident cases were reported in 2018, according to the World Health Organization. In the United States, incidence and mortality are decreasing, while incidence rates are increasing in other parts of the world. The highest incidence rates are in Australia, New Zealand, Europe, and North America, while the lowest rates are found in Africa and South-Central Asia. These geographic differences can be attributed to diet, environmental exposure, and genetics.
Lung cancer is the second most common cancer with approximately 2.0 million new cases of lung cancer reported in 2018. Cigarette smoking is the dominant risk factor associated with lung cancer across all age groups, with approximately 80% of male and 45% of female lung cancer cases worldwide attributed to smoking. With a dramatic increase in cigarette smoking rates, especially in China.
Kirsten Rat Sarcoma (KRAS) is a downstream signaling molecule in the EGFR cellular pathway with roles in cell growth and proliferation. It is commonly mutated in both CRC (39%) and NSCLC (25%) with the most frequent mutations in codons 12 and 13 causing over-activation of KRAS, which results in excessive cellular proliferation and tumor growth. While similar KRAS mutations are found in CRC and NSCLC, the frequency of the mutations differs between the two cancer types. In NSCLC, KRAS mutations are observed at a higher frequency in patients who have had significant exposure to tobacco.
The model covers KRAS Sanger sequencing Tests, KRAS Nucleic Acid Amplification Tests (NAAT) and KRAS Other Tests.
Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.
Key Inclusions of the market model are:
Currently marketed KRAS Tests and evolving competitive landscape:
Global, Regional and Country level market specific insights:
Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.
Companies covered: F. Hoffmann-La Roche Ltd, Qiagen NV, Agilent Technologies Inc, Illumina Inc, Thermo Fisher Scientific Inc, Abbott Laboratories, NimaGen BV, Mesa Laboratories Inc, New England Biolabs Inc, Amoy Diagnostics Co Ltd, HLB PanaGene Co Ltd, EntroGen, Inc, Sysmex Corp, Biocartis Group NV, and others
Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.
This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -
The model will enable you to -
Not Applicable